Guardant Health, Inc.
NASDAQ:GHMedical - Diagnostics & Research
+$2.67 today
- Market cap
- $19.64B
- Beta
- 1.62
- P/E (TTM)
- -39.9
- EPS (TTM)
- -$3.30
Volume 1.50M
Average 2.21M
GH Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Guardant Health, Inc.NASDAQ: GH
Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026
Income tax expense growth accelerates
Q3 FY2026 income tax expense of $343K rose 152.2% year over year, ahead of the -170.1% change in trailing-twelve-month income tax expense. Sequentially, it rose 85.4% from the prior quarter.
Context
- Income tax expense amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Income tax expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +152.2% holds above the trailing-twelve-month pace of -170.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- (1.26M) USD
- Year-over-year change
- -198.4%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.26M) | -198.4% |
| FY2024 | 2024-12-31 | 1.28M | +87.4% |
| FY2023 | 2023-12-31 | 685K | -39.9% |
| FY2022 | 2022-12-31 | 1.14M | +279.7% |
| FY2021 | 2021-12-31 | 300K | — |
Income Tax Expense vs competitors
How GH compares with its peers on the latest reported figures
- GH's LTM Sep 2026 income tax expense of -$827K is the 5th highest of the 10 companies compared; the peer median is -$2.67M.
- Its year-over-year change of -170.1% is the 7th highest of 9, against a peer median of +4.0%.
- Income tax expense amounts to 0.1% of revenue for GH, versus a peer median of 0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $194K | +40.6% | — | 0.0% |
| LTM Mar 2026 | $100K | +100.4% | — | 0.0% | |
| LTM Mar 2026 | $30K | +66.7% | -19.3% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | -$827K | -170.1% | — | 0.1% | |
| LTM Jun 2026 | -$2.67M | -89.0% | — | 0.3% | |
| LTM Mar 2026 | -$4.82M | -269.2% | — | 1.4% | |
| LTM Mar 2026 | -$7.91M | -3.5% | — | 2.5% | |
| LTM Jun 2026 | -$60.36M | -33998.9% | — | 2.2% | |
| LTM Jun 2026 | -$137.88M | +11.5% | — | 83.4% | |
| Peer median (excluding GH) | -$2.67M | +4.0% | -19.3% | 0.3% | |
Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 373.65M | 449.54M | 563.95M | 739.02M | 982.02M |
| Cost of Revenue | 122.91M | 156.33M | 227.05M | 289.8M | 349.01M |
| Gross Profit | 250.74M | 293.21M | 336.9M | 449.22M | 633.01M |
| Gross Margin | 67.1% | 65.2% | 59.7% | 60.8% | 64.5% |
| Research & Development | 263.22M | 373.81M | 367.19M | 347.75M | 364.19M |
| Selling, General & Admin | 398.52M | 463.78M | 451.03M | 545.06M | 706.07M |
| Operating Expenses | 661.74M | 837.59M | 901.62M | 892.81M | 1.07B |
| Depreciation & Amortization | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M |
| EBITDA | (359.62M) | (614.91M) | (433.31M) | (390.12M) | (373.91M) |
| EBITDA Margin | -96.2% | -136.8% | -76.8% | -52.8% | -38.1% |
| Operating Income | (411M) | (544.38M) | (564.73M) | (443.59M) | (437.25M) |
| Operating Margin | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% |
| Interest Income | 3.93M | 6.07M | 35.37M | 53.69M | 34.1M |
| Interest Expense | 2.58M | 2.58M | 2.58M | 2.58M | 3.9M |
| Other Income / Expenses | 26.53M | (109.07M) | 85.96M | 8.51M | 19.71M |
| Income Before Tax | (384.47M) | (653.45M) | (478.76M) | (435.09M) | (417.54M) |
| Pre-Tax Margin | -102.9% | -145.4% | -84.9% | -58.9% | -42.5% |
| Income Tax Expense | 300K | 1.14M | 685K | 1.28M | (1.26M) |
| Net Income | (405.67M) | (654.59M) | (479.45M) | (436.37M) | (416.28M) |
| Net Margin | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% |
| EPS (Basic) | (4.00) | (6.41) | (4.28) | (3.56) | (3.32) |
| EPS (Diluted) | (4.00) | (6.41) | (4.28) | (3.56) | (3.32) |
| Weighted Avg Shares | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M |
| Weighted Avg Shares (Diluted) | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M |
Guardant Health, Inc.
NASDAQ:GH
Intrinsic Alpha fair value
Locked
Current Price
$145.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.